Discover what’s possible with Emgality1
Emgality® is the first and only calcitonin gene-related peptide (CGRP) antibody approved for both migraine and episodic cluster headache in adults1,2
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085.